gip and glp-1 receptor agonist Mechanisms of action therapeutic applications of and dual GIP/GLP-1 agonists New Weight-Loss Drugs Are Poised
Description
Zhang Y, Chen R, Jia Y, Chen M, Shuai Z
Between August 2021 and 2023, 40.3% of Americans had a body mass index (BMI) 30
Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-m)
In addition, a meta-analysis was performed comparing pancreatitis events and exposure (patient-years) using Comprehensive Meta-Analysis version 2.2.064 (Englewood, NJ, USA), calculating the rate ratios and their 95% CIs, and the p value or difference
